Genentech, Inc.

Foundation Medicine, Inc.

F. Hoffmann-la Roche Ag

Richard Bourgon

Sanjeev Mariathasan

Priti Hegde

Carlos Bais

Gregg Fine

Thomas Sandmann

Roman Yelensky

Philip James Stephens

Garrett Michael Frampton

Heidi S Phillips

James Xin Sun

David Fabrizio

Marcin Kowanetz

Heidi Phillips

The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on somatic mutation levels of genes of the invention (e.g., somatic mutation levels in a tumor sample obtained from the patient).

Therapeutic and diagnostic methods for cancer

The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor-infiltrating immune cells in a tumor sample obtained from the patient) and/or based on the determination of a tumor sample subtype.

This invention concerns methods of treating a patient diagnosed with glioblastoma comprising administering to said patient a therapy comprising an effective amount of an anti-VEGF antibody and a chemotherapeutic.

Combination therapy for the treatment of glioblastoma

The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients having glioblastomas who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.

Diagnostic methods and compositions for treatment of glioblastoma

Method of treatment for glioblastoma by administering a VEGF antagonist

Growing community of inventors

South San Francisco, CA, United States of America

Richard Bourgon